List of Excipients in Branded Drug EDECRIN

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	EDECRIN	ethacrynic acid	25010-215	LACTOSE
Bausch Health US LLC	EDECRIN	ethacrynic acid	25010-215	MAGNESIUM STEARATE
Bausch Health US LLC	EDECRIN	ethacrynic acid	25010-215	SILICON DIOXIDE
Bausch Health US LLC	EDECRIN	ethacrynic acid	25010-215	TALC

Edecrin Excipient Strategy and Commercial Opportunities for Ethacrynic Acid

Last updated: October 9, 2026

Edecrin contains ethacrynic acid, a non-sulfonamide loop diuretic approved for treating edema associated with congestive heart failure, hepatic disease, renal disease and other conditions. Its commercial opportunity is niche rather than mass-market. The strongest opportunities are differentiated oral tablets, lactose-free formulations, pediatric and geriatric dosage forms, and sterile injectable presentations.

The reference product is an established small-molecule drug with no biosimilar exposure and limited patent barriers. Commercial success depends more on reliable supply, formulation tolerability, manufacturing quality, regulatory execution and access to a small specialist market than on exclusivity.

What is Edecrin and how is ethacrynic acid used?

Edecrin is the brand name for ethacrynic acid. The product is primarily associated with 25 mg oral tablets. Ethacrynic acid produces diuresis by inhibiting the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle.

Its principal labeled uses include edema associated with:

• Congestive heart failure
• Hepatic cirrhosis
• Renal disease, including nephrotic syndrome
• Other conditions requiring potent diuresis

Ethacrynic acid differs from furosemide, bumetanide and torsemide because it is not a sulfonamide-containing loop diuretic. That characteristic creates a specialist opportunity for patients with a documented serious sulfonamide hypersensitivity history, although clinical use remains subject to physician judgment.

The drug also carries important safety limitations. Excessive diuresis can produce dehydration, electrolyte depletion, hypotension and renal impairment. Ototoxicity is a material risk, particularly with rapid intravenous administration, high doses or concomitant ototoxic medicines. The label also identifies gastrointestinal adverse effects, including abdominal pain and gastrointestinal bleeding risks [1].

What excipients are used in Edecrin tablets?

The Edecrin tablet formulation uses conventional oral solid-dose excipients. The FDA prescribing information identifies the following inactive ingredients:

Excipient	Likely functional role
Lactose monohydrate	Diluent and tablet-mass former
Microcrystalline cellulose	Diluent and compression aid
Pregelatinized starch	Binder and disintegrant
Sodium starch glycolate	Superdisintegrant
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and flow aid

These excipients indicate an immediate-release compressed-tablet strategy. The formulation does not depend on a complex controlled-release polymer system, lipid vehicle or specialized delivery platform.

The principal formulation liabilities are lactose exposure, moisture sensitivity, powder-flow consistency, blend uniformity and the possibility of variable dissolution if manufacturing parameters are poorly controlled. Ethacrynic acid’s low aqueous solubility makes particle size, wetting, granulation and disintegration relevant to dissolution performance.

The current excipient profile is commercially conventional. That reduces manufacturing complexity but also limits differentiation unless a follow-on product solves a specific patient or supply problem.

What formulation patents protect Edecrin?

No active formulation patent is generally understood to create a material barrier to development of conventional ethacrynic acid tablets. Ethacrynic acid was approved in the 1960s, and the core composition-of-matter and early formulation rights have long expired.

A current developer should still review:

• FDA Orange Book patent listings for the applicable Edecrin NDA
• Approved-label differences between the reference product and generic products
• Any active method-of-use listings
• Device or packaging rights associated with injectable presentations
• Jurisdiction-specific patent registers outside the United States

The relevant commercial conclusion is that the opportunity is primarily a generic or reformulation opportunity rather than a protected innovator opportunity. The absence of a meaningful blocking patent estate does not eliminate regulatory or technical barriers. Bioequivalence, stability, dissolution, content uniformity and supply reliability remain decisive.

What is the Orange Book status of Edecrin?

Edecrin is an FDA-approved small-molecule reference product. The FDA Orange Book is the controlling source for current NDA, ANDA, therapeutic-equivalence and patent-listing information [2].

For an oral ethacrynic acid tablet, the likely regulatory pathway is an abbreviated new drug application, provided the applicant can demonstrate pharmaceutical equivalence and bioequivalence to the listed reference product. A new formulation that changes route, dosage form, release profile or clinical use may require a 505(b)(2) application rather than a conventional ANDA.

The commercial assessment is:

Regulatory issue	Commercial implication
Small-molecule drug	Generic development is available
Long-established approval	No meaningful new-drug exclusivity is expected
Conventional immediate-release tablet	ANDA pathway may be appropriate
New oral liquid or altered dosage form	505(b)(2) pathway may be required
Injectable product	Sterile manufacturing and product-specific regulatory work are required
No biosimilar pathway	Biosimilar competition is irrelevant

A prospective applicant should treat the Orange Book listing as a live regulatory record rather than rely on historical patent information.

When does Edecrin lose exclusivity?

Edecrin’s original regulatory and patent exclusivity expired decades ago. The product is therefore exposed to generic competition and does not have the exclusivity profile of a recently approved branded medicine.

The remaining commercial protection is based on:

• Brand recognition among specialists
• Prescriber familiarity
• Supply continuity
• Limited competition in the non-sulfonamide loop-diuretic segment
• Hospital and specialty-pharmacy contracting
• Formulation or presentation differentiation

There is no biologic exclusivity period, reference-product interchangeability issue or biosimilar substitution framework. Ethacrynic acid is a conventional small molecule.

What generic entry risks exist for Edecrin?

Generic entry risk is structurally high because the product is old, the dosage form is technically familiar and the core patents have expired. The market may still be commercially difficult because demand is narrow and manufacturing economics can be unfavorable.

Potential generic entrants include manufacturers with:

• Existing diuretic portfolios
• Low-cost oral solid-dose capacity
• Access to hospital or specialty distribution
• Experience with small-volume products
• Ability to maintain long-term supply despite modest sales

The largest risk to an incumbent is not necessarily a large number of entrants. One reliable ANDA holder can pressure pricing, especially if the market has limited differentiation and pharmacy substitution is available.

Manufacturing failures may temporarily reduce competition. That creates price opportunities but also increases regulatory scrutiny and supply obligations. A company entering the market should avoid treating shortage-driven pricing as a durable business model.

What excipient strategy is most attractive for Edecrin?

1. Lactose-free immediate-release tablets

A lactose-free tablet is the most direct formulation opportunity. Replacing lactose with mannitol, dibasic calcium phosphate, additional microcrystalline cellulose or another suitable diluent could address patients with lactose intolerance and simplify positioning for institutions that prefer lactose-free oral products.

The formulation must preserve:

• Comparable dissolution
• Tablet hardness
• Low friability
• Chemical stability
• Content uniformity at the 25 mg strength
• Acceptable tablet size

Because the drug load is relatively low, blend uniformity is important. A direct-compression formulation may be possible, but dry granulation or wet granulation could improve flow and dose uniformity depending on the active pharmaceutical ingredient’s particle characteristics.

2. Low-sodium and low-irritant formulation

Patients receiving loop diuretics often have cardiovascular, renal or hepatic disease. Excipients should not add unnecessary sodium or gastrointestinal burden. A low-sodium formulation could support hospital and specialty use, although the product’s total sodium contribution must be assessed analytically rather than inferred from excipient names.

Avoiding unnecessary dyes, artificial flavors and high levels of poorly tolerated excipients could also improve use in medically complex patients.

3. Pediatric oral liquid

A liquid formulation could address patients unable to swallow tablets, including children and adults with feeding tubes. Ethacrynic acid’s solubility and chemical stability would determine whether the product should be:

• An aqueous solution
• A suspension
• A powder for reconstitution
• A pharmacy-compounded intermediate
• A ready-to-use unit-dose liquid

A suspension may be more practical than a true solution if solubility is inadequate. The product would require dose-uniformity controls, sedimentation studies, redispersibility testing, preservative evaluation and in-use stability data.

The commercial opportunity is limited by the small patient population but may support a premium price if it replaces extemporaneous compounding.

4. Geriatric-friendly tablets

A smaller tablet, scored tablet or easy-open packaging may improve adherence. An orally disintegrating tablet could provide an administration benefit, but it would require careful taste masking and moisture protection.

An ODT would have greater development risk than a conventional tablet because ethacrynic acid may produce an unpleasant taste and because the product must balance rapid disintegration with adequate mechanical strength.

5. Modified-release formulations

Modified release is a weaker opportunity. Ethacrynic acid is used for potent diuresis, and physicians may require flexible dose titration. Delaying or extending drug release could reduce the clinical control that makes immediate-release therapy useful.

A modified-release product could still be considered for selected chronic-use populations, but it would likely require clinical justification and a 505(b)(2) strategy. The development cost and regulatory burden would be materially higher than for a conventional generic tablet.

What injectable formulation opportunities exist for ethacrynic acid?

Ethacrynate sodium injection historically provided a parenteral option. An injectable product would target patients who cannot take oral medication or require rapid diuresis.

The opportunity is technically more demanding because sterile products require:

• Sterile API and excipient control
• Endotoxin and particulate testing
• Container-closure integrity
• Sterility assurance
• Compatibility data
• Dilution and infusion instructions
• Ototoxicity risk controls
• Robust stability data

A ready-to-use premixed infusion could reduce hospital preparation steps, but its commercial value would depend on clinical demand and institutional purchasing. A lyophilized vial may offer better stability but increases reconstitution steps.

The injectable segment is likely more defensible than a standard tablet because sterile manufacturing capacity is less common. It is also more exposed to supply-chain failures, hospital formulary decisions and procurement pricing.

How strong is the Edecrin patent estate?

The patent estate is weak from an exclusivity perspective but potentially manageable from an entry perspective.

Patent category	Assessment
Original compound patents	Expired
Original tablet patents	Expired or commercially irrelevant
Core method-of-use patents	No expected blocking exclusivity for standard labeled use
New formulation patents	Potentially available for a differentiated product
Manufacturing-process patents	Possible, but difficult to use against conventional generic entry
Device patents	Relevant only if a specialized delivery or packaging system is developed

New patents could potentially cover a specific liquid, solid dispersion, particle-size distribution, stable injectable composition or delivery system. A broad patent on “ethacrynic acid with conventional excipients” would face substantial validity and obviousness risks because the active ingredient and ordinary tablet excipients are longstanding.

Patent strength would be higher for a narrowly defined formulation that demonstrates an unexpected technical effect, such as improved dissolution, enhanced stability, reduced degradation or improved dose uniformity.

Which companies are challenging or competing with Edecrin?

The primary competitive set is not limited to Edecrin-branded products. Ethacrynic acid competes clinically with:

• Furosemide
• Bumetanide
• Torsemide
• Other loop or high-ceiling diuretics

Furosemide is the dominant economic comparator because of its low cost and broad availability. Ethacrynic acid’s differentiation is its non-sulfonamide structure and use in selected patients who cannot receive conventional sulfonamide loop diuretics.

Generic manufacturers may compete through ANDA products, while branded suppliers can compete through reliable availability, specialty distribution and hospital contracting. The market is fragmented enough that product shortages or discontinuations can materially affect prescriber behavior.

What licensing and commercial deal opportunities exist?

Edecrin offers limited value as a conventional licensing asset but may support targeted transactions involving:

• Rights to a lactose-free or pediatric formulation
• Regional commercialization rights
• Injectable development rights
• Contract manufacturing
• Hospital supply agreements
• Specialty-pharmacy distribution
• Technology transfer for a stable liquid or sterile presentation

A licensing deal would be more attractive if the partner controls an established diuretic portfolio or has hospital access. A standalone ethacrynic acid asset would have limited negotiating leverage without a differentiated formulation, reliable supply advantage or regulatory designation.

Potential transaction structures include a regional license, supply-and-distribution agreement, co-development arrangement for a 505(b)(2) product or acquisition of an approved small-volume product line.

What revenue exposure does Edecrin create?

Edecrin is unlikely to provide blockbuster revenue. Its value lies in niche pricing, limited direct substitutes for certain patients and the ability to add a small product to an existing commercial portfolio.

Revenue is exposed to:

• Generic substitution
• Small addressable patient population
• Hospital purchasing pressure
• Product discontinuation risk
• Shortage-driven demand volatility
• Physician preference for lower-cost furosemide or bumetanide
• Safety concerns associated with potent diuresis and ototoxicity

The best commercial profile is a modest-volume product with high supply reliability and low manufacturing complexity. A company should not rely on broad primary-care adoption. The principal prescribers are likely to be cardiologists, nephrologists, hepatologists, hospitalists and other specialists managing complex edema.

What is the best commercial formulation strategy for Edecrin?

The strongest near-term strategy is a differentiated immediate-release oral tablet with:

1. A lactose-free excipient system.
2. Robust dissolution across relevant pH conditions.
3. Strong content uniformity at the 25 mg strength.
4. Simple packaging with moisture protection.
5. Reliable long-term supply.
6. A regulatory pathway aligned with the final dosage form.
7. Optional pediatric or feeding-tube-compatible liquid development.

An injectable product may offer greater differentiation but requires higher capital investment and sterile manufacturing capability. A modified-release product has the weakest risk-adjusted profile unless supported by a clear clinical use case.

Key Takeaways

• Edecrin is ethacrynic acid, an established non-sulfonamide loop diuretic.
• The original patent and regulatory exclusivity have expired.
• No biosimilar risk exists because ethacrynic acid is a small molecule.
• Conventional tablets have limited formulation differentiation.
• Lactose-free tablets are the clearest low-risk opportunity.
• Pediatric liquids, feeding-tube formulations and geriatric-friendly tablets offer targeted 505(b)(2) opportunities.
• Injectable ethacrynate sodium could provide stronger market differentiation but requires sterile manufacturing and higher investment.
• The principal competitive threat is generic entry and substitution by furosemide, bumetanide and torsemide.
• Commercial value depends on supply reliability, specialist positioning and formulation execution rather than patent exclusivity.
• A broad excipient patent would likely be weak; narrowly defined stability, dissolution or delivery improvements would have better patent prospects.

FAQs About Edecrin Excipients and Commercial Development

Is Edecrin lactose-free?

The Edecrin tablet formulation identified in the FDA labeling contains lactose monohydrate. A lactose-free generic or reformulated product could provide a practical differentiation point [1].

Can ethacrynic acid be developed as an oral liquid?

Yes. An oral liquid could be developed as a solution, suspension or powder for reconstitution, but solubility, chemical stability, dose uniformity and in-use stability would determine the appropriate design.

Is Edecrin eligible for a generic ANDA?

A conventional immediate-release tablet may be eligible for an ANDA if it matches the reference product in active ingredient, dosage form, strength, route and other applicable requirements. A materially different dosage form may require a 505(b)(2) application.

Does ethacrynic acid have biosimilar competition?

No. Ethacrynic acid is a chemically synthesized small molecule. Competition would arise from generic products, reformulations and alternative diuretics, not biosimilars.

What is the most defensible Edecrin formulation patent strategy?

The strongest strategy would focus on a specific, reproducible technical improvement such as enhanced stability, improved dissolution, reduced degradation, a stable pediatric liquid or a differentiated sterile composition. Broad claims covering ethacrynic acid with routine tablet excipients would face substantial prior-art risk.

References

1. U.S. Food and Drug Administration. (n.d.). Edecrin (ethacrynic acid) tablets: Prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.

4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

5. DailyMed. (n.d.). Edecrin: Ethacrynic acid tablet labeling. National Library of Medicine.